HCPCS
J2778
0.1 mg = 1 unit
Phase 1
Identify what you're billing
Confirm the unit basis (0.1 mg!), dose, NDC, and whether a biosimilar was actually administered.
Lucentis vs. biosimilars — the unit math is the trap HCPCS verified May 2026
The single most common biller error on ranibizumab claims: treating J2778 as a 1 mg unit code.
HCPCS J2778 — "Injection, ranibizumab, 0.1 mg" — uses an unusual 0.1 mg unit basis.
This is different from most J-codes (which are denominated in 1 mg or 10 mg increments) and different from
the related Eylea HD code J0177 (1 mg = 1 unit). For ranibizumab, you must
multiply the milligram dose by ten to get billable units.
# Ranibizumab dose → J2778 units
0.5 mg dose (wAMD, RVO, mCNV) = 5 units
0.3 mg dose (DME, DR) = 3 units
0.2 mg dose (ROP, pediatric) = 2 units
# Rule of thumb
units = mg × 10
The same 0.1 mg unit basis applies to all three current biosimilars (Q5124 Byooviz, Q5128 Cimerli, and the not-yet-coded Nufymco). Susvimo's J2779 also uses 0.1 mg units, but Susvimo is a different delivery system and is not a Lucentis substitute.
Top biller error: billing 1 unit of J2778 for a 0.5 mg dose, or billing “0.5 units.”
Both deny. The correct quantity for the standard wAMD dose is 5 units of J2778. A 0.3 mg DME/DR
dose is 3 units. Always cross-check the chart strength (mg) against the units field on the claim.
Biosimilars — three products, three coding patterns FDA verified May 2026
Identify which ranibizumab the chart actually documents before pulling the J-code. The drug name on the bottle determines the code; "ranibizumab" alone is not enough.
| Brand | Generic | HCPCS | Manufacturer | Interchangeable? | Approved doses |
|---|---|---|---|---|---|
| Lucentis (reference) | ranibizumab | J2778 |
Genentech / Roche | n/a (reference) | 0.5 mg, 0.3 mg, 0.2 mg |
| Byooviz | ranibizumab-nuna | Q5124 |
Samsung Bioepis / Biogen | No (1st ophthalmology biosimilar; FDA Sep 2021) | 0.5 mg only |
| Cimerli | ranibizumab-eqrn | Q5128 |
Coherus BioSciences | Yes — full label parity with Lucentis | 0.5 mg and 0.3 mg |
| Nufymco | ranibizumab-leyk | No Q-code yet — bill J3590 (commercial) or C9399 (HOPD) until CMS issues one |
Formycon / Bioeq (US distribution: Zydus) | Yes — 3rd interchangeable; FDA approval Dec 18, 2025 | 0.5 mg and 0.3 mg (per label parity) |
Nufymco coding workaround: until CMS issues a permanent Q-code (typically a 3–9 month
process from FDA approval), bill Nufymco doses under unclassified J-code
J3590 on CMS-1500
commercial claims, or C9399 on hospital outpatient. Include the brand name, NDC, dose, and
invoice in the claim narrative; expect manual review and slower payment. Re-code to the permanent Q-code
once published.
Reading the chart for the right code. "Ranibizumab" alone is not a code-determining label.
Always look for the brand on the syringe label, the NDC documented at administration, or the medication
order showing brand. A Cimerli administration coded as J2778 is a denial (or worse, an audit risk for
upcoded reimbursement, since reference Lucentis ASP runs higher than biosimilar ASP).
Dosing per indication FDA label, BLA 125156
Source: DailyMed Lucentis prescribing information. Six FDA-approved indications across two strength formulations.
| Indication | Dose | Schedule | J2778 units / dose |
|---|---|---|---|
| Neovascular (wet) AMD | 0.5 mg (10 mg/mL) | Monthly | 5 |
| Macular edema following RVO | 0.5 mg (10 mg/mL) | Monthly | 5 |
| Diabetic Macular Edema (DME) | 0.3 mg (6 mg/mL) | Monthly | 3 |
| Diabetic Retinopathy (DR) | 0.3 mg (6 mg/mL) | Monthly | 3 |
| Myopic CNV (mCNV) | 0.5 mg (10 mg/mL) | Monthly up to 3 months (re-treatment if needed) | 5 |
| Retinopathy of Prematurity (ROP) | 0.2 mg pediatric | Per label | 2 |
Two strengths, two NDC families. The 0.5 mg presentations use the 10 mg/mL solution (NDC root
50242-080); the 0.3 mg presentations use the 6 mg/mL solution (NDC root 50242-082).
Both are 0.05 mL injection volume. Submitting the wrong NDC for the documented indication is a common rejection
reason because the strength on the NDC must reconcile to the units billed.
NDC reference FDA NDC Directory verified May 2026
Genentech labeler code 50242. Lucentis has multiple presentations across two concentrations.
| NDC (10-digit) | NDC (11-digit, claim form) | Strength | Package |
|---|---|---|---|
50242-080-01 |
50242-0080-01 |
0.5 mg (10 mg/mL) | Single-use vial |
50242-080-02 |
50242-0080-02 |
0.5 mg (10 mg/mL) | Single-use vial in carton |
50242-080-03 |
50242-0080-03 |
0.5 mg (10 mg/mL) | Prefilled syringe (PFS), glass |
50242-080-88 |
50242-0080-88 |
0.5 mg (10 mg/mL) | Prefilled syringe |
50242-082-01 |
50242-0082-01 |
0.3 mg (6 mg/mL) | Single-use vial |
50242-082-03 |
50242-0082-03 |
0.3 mg (6 mg/mL) | Prefilled syringe |
50242-082-88 |
50242-0082-88 |
0.3 mg (6 mg/mL) | Prefilled syringe |
11-digit NDC required on most claim forms. Pad the middle segment with a leading zero
(50242-0080-01). Use the
N4 qualifier in CMS-1500 Box 24A shaded area, with
unit of measure (ML) and quantity (e.g., N450242008001ML0.05). Strength on the NDC must match
the units billed: a 0.3 mg dose of J2778 (3 units) cannot reconcile against a 0.5 mg NDC.
Phase 2
Code the claim
CPT 67028 + per-eye laterality + NCCI bundling pitfalls.
CPT 67028 & bilateral rules CPT verified May 2026
Intravitreal injections have unique laterality rules — per-eye billing, RT/LT preferred over modifier 50.
| Code | Description | Notes |
|---|---|---|
67028 |
Intravitreal injection of a pharmacologic agent (separate procedure) | Always pair with the J2778 (or biosimilar) drug line on the same claim. Append RT or LT for laterality. |
Bilateral same-day injections — RT/LT, not modifier 50
For bilateral Lucentis injections on the same date of service, most payers require two separate line items:
- Line 1:
67028-RT, 1 unit, full fee - Line 2:
67028-LT, 1 unit, full fee
Some commercial payers accept the alternative single-line format with modifier 50:
67028-50, 1 unit, fee doubled
Per AAPC: "It is important to check with individual payers as some may require the procedure to be billed on two separate lines with -RT and -LT modifiers instead of using -50." Modifier 50 is not preferred for retina; RT/LT is the safer default.
Drug billing for bilateral: bill J2778 twice as well — one drug line per eye, each with
the matching RT or LT modifier. Each eye gets the appropriate units (5 for 0.5 mg, 3 for 0.3 mg) of J2778
plus 1 unit of 67028.
Modifiers CMS verified May 2026
RT / LT — required for laterality
Append RT (right eye) or LT (left eye) to BOTH the J2778 drug line and the 67028 admin line. Without laterality, payer systems can't reconcile bilateral claims and will deny one or both lines. Modifier 50 is generally not preferred for retina coding.
JZ — required when no drug discarded
Effective July 1, 2023, CMS requires the JZ modifier on all single-dose container claims when no drug is discarded. Lucentis vials and PFS are sized to a 0.05 mL dose, so wastage is essentially zero on a clean injection. JZ applies by default to nearly every Lucentis claim. Per Retina Today: "Retina drugs are frequently reported with modifier -JZ." JZ is mandatory on Q5124, Q5128, and Nufymco (J3590/C9399) claims for the same reason.
JW — rarely applies
Use JW only if at least one billable unit (0.1 mg) was actually wasted. Because Lucentis vials and PFS are single-dose, sized exactly to the 0.05 mL injection volume, this is uncommon. If JW is appropriate, the wasted units are reported on a separate line from the administered units, with documentation in the medical record.
Modifier 25 — same-day E/M
Append modifier 25 to the E/M code when a significant, separately identifiable E/M service is performed on the same day as the injection. Routine pre-injection workup is bundled. New clinical concerns or treatment-decision visits qualify; routine "see how the eye looks before the shot" does not.
NCCI bundling — OCT, fundus photo, and 67028 NCCI verified May 2026
Ophthalmology-specific bundling that drives a large share of retina claim denials.
CMS National Correct Coding Initiative (NCCI) bundles several diagnostic services with 67028 when performed same-day:
| Code | Service | NCCI relationship to 67028 |
|---|---|---|
92133 | SCODI optic nerve (OCT) | Bundled same-day; XU/59 unbundling possible with documentation |
92134 | SCODI retina (OCT) | Bundled same-day; XU/59 unbundling possible with documentation |
92250 | Fundus photography | Bundled same-day; XU/59 unbundling possible with documentation |
| Established-pt E/M (99211–99215) | Office visit | Bundled; use modifier 25 if separately identifiable |
| Eye visit codes (92012, 92014) | Comprehensive eye exam | Not bundled with 67028 by NCCI |
Common denial: billing OCT (92134) on the same date as 67028 without a modifier. NCCI will
deny the bundled service. To unbundle, append
XU or 59 to the OCT line, with
documentation in the medical record showing the OCT informed a treatment decision distinct from the injection
itself (e.g., evaluating disease progression for an interval-extension or switch decision). Without proper
documentation, the unbundling is audit-vulnerable.
Eye visit codes (92012, 92014) are NOT bundled with 67028, so they're often the better choice for the visit portion of an injection encounter.
ICD-10-CM diagnosis codes FY2026 verified May 2026
Use the most specific code supported by the encounter documentation. Laterality character must match the RT/LT modifier on 67028.
| ICD-10 | Description | Use for |
|---|---|---|
H35.32xx | Exudative age-related macular degeneration | Wet AMD; 5th & 6th characters specify laterality and stage |
E11.311 / E11.319 | Type 2 DM with unspec/with macular edema | DME in T2DM |
E10.311 / E10.319 | Type 1 DM with unspec/with macular edema | DME in T1DM |
E11.359 / E10.359 | DM with proliferative diabetic retinopathy, unspec | DR by severity (add specific 5th/6th char) |
H34.81xx | Branch retinal vein occlusion (BRVO) | Macular edema following BRVO |
H34.83xx | Tributary (branch) retinal vein occlusion | Alternative BRVO coding |
H44.2x + H35.05 | Degenerative myopia + retinal neovascularization | Myopic CNV (mCNV) |
H35.10–H35.17 | Retinopathy of prematurity (ROP), by zone & stage | Pediatric ROP |
H35.81 | Retinal edema | Adjunct dx; not standalone for J2778 |
Pair the diagnosis with the laterality modifier on the procedure line. ICD-10 codes carry their
own laterality character (e.g., H35.3211 = wAMD right eye stage 1); the RT/LT on 67028 must match. Mismatch
between Dx laterality and procedure laterality is a denial trigger.
Site of care & place of service Verified May 2026
Lucentis is administered in-office or in an ASC. Home administration does not apply for intravitreal injections.
Intravitreal injections must be performed by an ophthalmologist or qualified retina specialist in a setting with sterile injection capability. Home administration is not a valid pathway for Lucentis, so home-infusion HCPCS codes (S9329, S9379, 99601, G0089) do not apply. The only legitimate sites of care are physician office, ophthalmology-based ASC, and hospital outpatient.
| Setting | POS | Claim form | Electronic |
|---|---|---|---|
| Physician / retina office | 11 | CMS-1500 | 837P |
| Ambulatory surgery center (ophth ASC) | 24 | CMS-1500 | 837P |
| Hospital outpatient | 22 | UB-04 / CMS-1450 | 837I |
| On-campus hospital outpatient | 19 | UB-04 / CMS-1450 | 837I |
Payer site-of-care steering
Both UnitedHealthcare and Aetna apply site-of-care utilization management to ophthalmology anti-VEGF injections, generally favoring office (POS 11) and ophth ASC (POS 24) over hospital outpatient (POS 19/22) due to higher facility fees. If your practice operates under a hospital's billing TIN, expect a payer challenge for hospital outpatient billing.
POS choice affects reimbursement. Office (POS 11) and ASC (POS 24) generally pay at higher
physician-fee-schedule rates for the drug, while hospital outpatient (POS 19/22) bills under OPPS/APC
bundling rules with separate facility-fee considerations. Confirm your payer's preferred site before
scheduling.
Claim form field mapping Genentech 2025 + Retina Today
CMS-1500 / 837P (physician office, ASC; POS 11/24).
| Information | CMS-1500 box | Notes |
|---|---|---|
| NDC qualifier + 11-digit NDC + UoM + qty | 24A shaded area | Format: N450242008001ML0.05 (0.5 mg PFS) or N450242008201ML0.05 (0.3 mg PFS) |
| HCPCS J2778 + RT/LT + JZ | 24D (drug line) | Units = mg × 10 (5 for 0.5 mg, 3 for 0.3 mg, 2 for 0.2 mg) |
| Drug units | 24G | 5, 3, or 2 |
| CPT 67028 + RT/LT | 24D (admin line) | One unit per eye |
| ICD-10 | 21 | Specific H35.32xx / E1x.31x / H34.81xx / H44.2x / H35.10–17 |
| Dates of service | 24A | Same date for drug + admin lines |
| NPI | 17b | Rendering provider |
| PA number (when required) | 23 | Required by UHC, Aetna, most BCBS |
Source: Retina Today — How to Create Clean Claims; Genentech Lucentis Billing & Coding documentation.
Phase 3
Get paid
Step therapy + biosimilar substitution are both real for Lucentis. Plan ahead.
Payer policy snapshot Reviewed May 2026
Lucentis is heavily step-gated and non-preferred at major commercial payers in 2026 due to biosimilar competition and the Avastin price gap.
| Payer | PA? | Step therapy? | Biosimilar substitution? | Quantity limit |
|---|---|---|---|---|
| UnitedHealthcare Ophth VEGF Inhibitors policy |
Yes | Yes — bevacizumab (Avastin) first; Lucentis non-preferred | Yes — biosimilar (Q5124 / Q5128) preferred over reference Lucentis | FDA-label dosing |
| Aetna CPB 0701; MA Ref 2507-A |
Yes | Yes — commercial requests bevacizumab trial; biosimilar pathway preferred | Yes — Cimerli/Byooviz preferred | FDA-label dosing |
| BCBS (most plans) e.g., Blue Shield CA |
Yes | Generally yes — bevacizumab trial or contraindication required | Plan-dependent — many require biosimilar substitution | FDA-label dosing |
Lucentis is the most-stepped anti-VEGF in 2026. Unlike Eylea HD (which has no biosimilar), Lucentis
faces a three-front squeeze: (1) off-label repackaged bevacizumab (Avastin) is ~$50–100/dose vs. ~$340 for
reference Lucentis; (2) Cimerli and Byooviz biosimilars are 30–40% cheaper than reference; and (3) Cimerli
and Nufymco are designated as interchangeable, allowing pharmacy-level substitution. Document the bevacizumab
trial (or a clear contraindication) AND confirm whether the payer mandates biosimilar substitution before
requesting a reference Lucentis authorization.
Why step therapy & biosimilar substitution here
Repackaged bevacizumab costs ~$50–100/dose vs. ~$340 for reference Lucentis and ~$200–240 for biosimilar ranibizumab. With three biosimilars now in the market — two of them interchangeable — commercial payers have multiple cheaper anti-VEGF pathways for cost containment, and Lucentis is the most expensive option in its molecular class. This is fundamentally different from drugs without biosimilar competition, where step therapy is usually limited to off-label alternatives.
Exception pathway for reference Lucentis
- Documented prior bevacizumab failure (typically ≥3 doses, with OCT measurements)
- Contraindication or intolerance to bevacizumab (e.g., prior thromboembolic event)
- Indication where Avastin lacks evidence (e.g., pediatric ROP — Lucentis is the labeled product)
- Documented intolerance or failure on a biosimilar (where biosimilar substitution is mandated)
Medicare reimbursement CMS Q2 2026 (live)
Quarterly ASP from CMS Part B Drug Pricing File. Refreshes automatically each quarter. Biosimilars trend 30–40% below reference Lucentis ASP.
Q2 2026 payment snapshot — J2778
Effective April 1 – June 30, 2026 · Based on 4Q25 ASP submissions
ASP + 6% (per unit)
$67.853
per 0.1 mg unit
0.5 mg dose (5 units)
$339.27
wAMD / RVO / mCNV
0.3 mg dose (3 units)
$203.56
DME / DR
Coverage
No NCD specific to Lucentis. The relevant MAC billing & coding article is A52451 ("Billing and Coding: Ranibizumab and biosimilars, Aflibercept, Aflibercept HD, Brolucizumab-dbll, Faricimab-svoa..."). All MACs cover J2778, Q5124, and Q5128 for FDA-approved on-label indications. Bill with a specific H35.32xx, E1x.31x/E1x.35x, H34.81xx, H44.2x, or H35.10–17 ICD-10.
Sequestration
Medicare ASP+6% is reduced by approximately 2% sequestration on the program payment side, effectively netting closer to ASP + 4.3% on the actual paid amount. The unit price shown above is the gross ASP+6% rate; net paid will be slightly lower.
Canonical code source: HCPCSdata J2778; CMS Part B Drug ASP Pricing File.
Patient assistance — Genentech Ophthalmology Co-pay (EyeOnCopay) Genentech verified May 2026
- Genentech Ophthalmology Co-pay Program (Lucentis): eligible commercially-insured patients may pay as little as $0 copay per Lucentis treatment
- Annual benefit cap: up to $15,000 per calendar year
- No income requirement for the copay program
- Excluded: patients enrolled in Medicare, Medicare Advantage, Medigap, Medicaid, VA, DoD, or TRICARE
- Enrollment: (855) 218-5307 or EyeOnCopay.com
- Genentech Patient Foundation: free drug for uninsured / underinsured patients meeting income requirements
- Independent foundations: support for Medicare patients via foundations like Patient Access Network (PAN) and HealthWell — verify open funds quarterly
Need to model what a specific patient will actually pay after copay assistance, deductible, coinsurance, and
OOP max? Run a CareCost Estimate — J2778 pre-loaded.
Phase 4
Fix problems
Wrong unit math, biosimilar mismatch, step-therapy denials, and laterality mismatches are the top four.
Common denials & how to fix them
| Denial reason | Common cause | Fix |
|---|---|---|
| Wrong units (1 instead of 5) | Treating J2778 as a 1 mg/unit code instead of 0.1 mg/unit | Resubmit with correct units: 0.5 mg = 5 units; 0.3 mg = 3 units; 0.2 mg = 2 units. Multiply mg dose by 10. |
| Wrong J-code (J2778 used for biosimilar) | Cimerli or Byooviz administered but billed as reference Lucentis | Resubmit Byooviz under Q5124, Cimerli under Q5128. Nufymco under J3590/C9399 (no permanent code yet). |
| NDC strength does not reconcile to units | 0.3 mg NDC root (50242-082) submitted with 5 units, or 0.5 mg NDC submitted with 3 units | Match NDC root to dose: 50242-080-xx for 0.5 mg / 5 units; 50242-082-xx for 0.3 mg / 3 units. |
| Step therapy not met | No documented bevacizumab trial; payer requires Avastin first | Submit bevacizumab trial documentation (3 doses, OCT measurements, response data) OR contraindication letter. |
| Biosimilar substitution required | Reference Lucentis requested when payer mandates Cimerli/Byooviz/Nufymco | Switch to the payer's preferred biosimilar OR document failure/intolerance/contraindication on the biosimilar. |
| Bundled diagnostic (OCT/fundus photo) | 92134/92250 billed same day as 67028 without modifier | Resubmit OCT/fundus photo line with modifier XU or 59 + medical-record documentation showing distinct medical necessity. |
| Laterality mismatch | RT/LT modifier doesn't match the ICD-10 laterality character | Match: H35.3211 (right eye) → 67028-RT + J2778-RT. Same date, same eye on every line. |
| Bilateral billed as modifier 50 | Payer requires RT/LT separate lines, not modifier 50 | Resubmit as two lines: 67028-RT + 67028-LT, full fee on each. Same for J2778 drug lines. |
| NDC format | 10-digit NDC submitted instead of 11-digit; missing N4 qualifier | Use N450242008001ML0.05 format in CMS-1500 Box 24A shaded area (pad middle with leading zero). |
| JZ missing | Single-dose vial / PFS claim without JZ modifier | Resubmit with JZ on the J2778 (or biosimilar) line. Required since 7/1/2023. |
Frequently asked questions
What is the HCPCS code for Lucentis?
Lucentis (ranibizumab) is billed under HCPCS J2778 — "Injection, ranibizumab, 0.1 mg." The
unit basis is 0.1 mg per unit — NOT 1 mg per unit. This is the most common
biller error: a 0.5 mg wAMD/RVO/mCNV dose is billed as 5 units, and a 0.3 mg DME/DR dose is
billed as 3 units. The 0.2 mg pediatric ROP dose is 2 units.
How many units do I bill for a Lucentis dose?
Units depend on the indication's dose. Wet AMD, RVO, and myopic CNV all use 0.5 mg = 5 units of J2778. Diabetic macular edema and diabetic retinopathy use 0.3 mg = 3 units. Pediatric retinopathy of prematurity (ROP) uses 0.2 mg = 2 units. Always multiply the milligram dose by 10 to get J2778 units, because the code is denominated in 0.1 mg increments.
What is the administration code for Lucentis?
CPT 67028 — "Intravitreal injection of a pharmacologic agent (separate procedure)." Bill
67028 with an RT (right eye) or LT (left eye) modifier. For bilateral same-day injections, most payers require
two separate line items with RT and LT, full fee on each — not modifier 50. Per AAPC, RT/LT is the safer
default for retina coding.
What HCPCS codes do the Lucentis biosimilars use?
Three biosimilars in market as of May 2026. Byooviz (ranibizumab-nuna, Samsung Bioepis/Biogen)
bills under Q5124 — first ophthalmology biosimilar, FDA September 2021, NOT interchangeable,
0.5 mg only. Cimerli (ranibizumab-eqrn, Coherus) bills under Q5128 —
interchangeable, full label parity covering both 0.3 mg and 0.5 mg doses. Nufymco
(ranibizumab-leyk, Formycon/Bioeq, US distribution by Zydus) was approved December 18, 2025 as the third
interchangeable biosimilar; it does NOT yet have a permanent Q-code and should be billed under
J3590 (commercial) or C9399 (hospital outpatient) until CMS issues a code. All three
biosimilars use the same 0.1 mg unit basis as J2778.
Does Lucentis require step therapy?
Yes — heavily. Lucentis is non-preferred at most major commercial payers in 2026. UnitedHealthcare requires bevacizumab (repackaged Avastin) first; Lucentis is the non-preferred branded option behind biosimilars. Most BCBS plans require prior authorization plus a documented Avastin trial unless there is a clear contraindication, intolerance, or an indication where Avastin lacks evidence. Biosimilar competition (Byooviz, Cimerli, Nufymco) and the off-label Avastin price gap drive this. Many payers also apply mandatory biosimilar substitution: a Lucentis request will be redirected to Byooviz or Cimerli even after step-therapy criteria are met.
What are the FDA-approved indications for Lucentis?
Six indications under BLA 125156: neovascular (wet) age-related macular degeneration (0.5 mg monthly); macular edema following retinal vein occlusion (0.5 mg monthly); diabetic macular edema (0.3 mg monthly); diabetic retinopathy (0.3 mg monthly); myopic choroidal neovascularization (0.5 mg monthly up to 3 months); and retinopathy of prematurity in pediatric patients (0.2 mg per label). Note that the DME/DR/ROP doses use a different concentration (6 mg/mL) than wAMD/RVO/mCNV (10 mg/mL) and have separate NDCs.
What is the Medicare reimbursement for J2778?
Medicare Part B reimburses J2778 at ASP + 6% per 0.1 mg unit. Q2 2026 ASP+6% is approximately
$67.853 per unit, putting a 0.5 mg dose (5 units) at roughly
$339.27 and a 0.3 mg dose (3 units) at roughly
$203.56 before sequestration. Sequestration (~2%) reduces actual paid to
roughly ASP + 4.3%. ASP is updated quarterly by CMS via the Part B Drug Pricing File.
Are 67028 and OCT (92133/92134) bundled by NCCI?
Yes. NCCI bundles 67028 with 92133/92134 (OCT scans) and 92250 (fundus photography) when performed same-day.
To unbundle, append modifier XU or 59 to the bundled code with documented separate
medical necessity (e.g., the OCT informed a treatment decision distinct from the injection itself). Eye visit
codes 92012/92014 are NOT bundled with 67028 by NCCI.
How is Susvimo (J2779) different from Lucentis (J2778)?
Susvimo is the same molecule (ranibizumab) but a fundamentally different product. It is a refillable
scleral-implanted port-delivery reservoir, not a syringe injection. The Susvimo formulation is 100 mg/mL
(10× more concentrated than Lucentis), the reservoir holds 0.02 mL, and CMS assigned a separate HCPCS
code: J2779 — "Injection, ranibizumab, via intravitreal implant (Susvimo), 0.1 mg." Susvimo
is NOT billed with CPT 67028; the implantation, refill-exchange, and removal procedures use distinct CPT
codes. After a voluntary recall in October 2022 for septum dislodgement, the product was re-released and is
currently approved for nAMD, DME, and DR. A dedicated Susvimo billing page is coming soon.
Reference
Sources & methodology
Every claim on this page is sourced. Methodology and review history below.
Source documents
- DailyMed — Lucentis (ranibizumab) Prescribing Information
- HCPCSdata — J2778 "Injection, ranibizumab, 0.1 mg"
- AAPC — HCPCS Q5124 (Byooviz, ranibizumab-nuna)
- AAPC — HCPCS Q5128 (Cimerli, ranibizumab-eqrn)
- AAPC — HCPCS J2779 (Susvimo)
- Drugs.com — Nufymco (ranibizumab-leyk) FDA approval history
- American Academy of Ophthalmology (AAO) — Biosimilars overview
- CMS MCD Article A52451 — Ranibizumab and biosimilars billing & coding
- CMS — Medicare Part B Drug ASP Pricing File
- UnitedHealthcare — Ophthalmologic VEGF Inhibitors policy
- Aetna CPB 0701 — VEGF Inhibitors for Ocular Indications
- Genentech EyeOnCopay — Lucentis Co-pay Program
- Retina Today — How to Create Clean Claims
- Retina Today — The Effect of Bilateral Rules on Retina Coding
- AAPC — CPT 67028
- CMS NCCI — National Correct Coding Initiative edit tables
- FDA — Ophthalmology biosimilars approvals
- Genentech — Lucentis HCP product page (billing & coding resources)
About this page
We maintain this page as a living reference. Medicare ASP pricing is bound to our underlying CareCost data layer and refreshes automatically when CMS publishes new quarterly files. Coding and policy content is reviewed at least quarterly and updated whenever a source document changes.
Found an error? Email hello@carecostestimate.com.
Refresh cadence
| Element | Cadence | How it's refreshed |
|---|---|---|
| Medicare ASP pricing | Quarterly | Auto-bound to CareCost ASP layer; updates on CMS file release. |
| Payer policies (UHC, Aetna, BCBS) | Semi-annual | Manual review against published payer policy documents. |
| HCPCS / CPT / NCCI rules | Annual | Reviewed against CMS HCPCS quarterly files, AMA CPT releases, and NCCI edit updates. |
| NDC, dosing, FDA label | Event-driven | Tied to manufacturer document version + FDA label revision date. |
| Biosimilar code map | Event-driven | Updated whenever CMS issues a new Q-code (notably watching for the Nufymco code assignment). |
Reviewer
Pending SME review. This page is staff-authored from primary sources (FDA, CMS, manufacturer,
payer documents — all linked above). Final review by our SME, Catherine Rose (CPC), is in progress.
Until that review is complete, treat this as a draft reference and verify each cited source for high-stakes claims.
Change log
- — Initial publication. ASP data: Q2 2026. FDA label: BLA 125156 (six indications: wAMD, RVO, DME, DR, mCNV, ROP). Biosimilars: Byooviz (Q5124, Sep 2021), Cimerli (Q5128, interchangeable), Nufymco (interchangeable, Dec 2025, code pending). Payer policies: UHC Ophth VEGF Inhibitors, Aetna CPB 0701, Blue Shield CA. Susvimo (J2779) cross-link added.
Methodology
Every claim on this page is sourced inline. Pricing reflects the current CMS Part B Drug ASP Pricing File. Payer policies are read directly from each payer's published medical policy documents. We do not paraphrase from billing-software vendor blogs. When manufacturer guidance and payer policy conflict (as happens with bilateral injection coding, biosimilar substitution mandates, and step-therapy rules), we surface the conflict rather than picking a side.